Toripalimab

Therapeutic indications

Toripalimab is indicated for:

Nasopharyngeal carcinoma

Population group: only adults (18 years old or older)

Toripalimab is indicated, in combination with cisplatin and gemcitabine, for the first-line treatment of adults with metastatic or with recurrent, locally advanced nasopharyngeal carcinoma (NPC).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

240 mg every 3 weeks until disease progression, unacceptable toxicity, or up to 24 months

Recurrent unresectable or metastatic nasopharyngeal carcinoma

Population group: only adults (18 years old or older)

Toripalimab is indicated, as a single agent, for the treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

3 mg/kg every 2 weeks until disease progression or unacceptable toxicity

Contraindications

Toripalimab is contraindicated in the following cases:

Lactation

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.